Raymond James Financial Inc. Makes New Investment in Genmab A/S (NASDAQ:GMAB)

Raymond James Financial Inc. bought a new position in Genmab A/S (NASDAQ:GMAB) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 118,002 shares of the company’s stock, valued at approximately $2,463,000.

Several other hedge funds and other institutional investors have also bought and sold shares of GMAB. Aigen Investment Management LP purchased a new stake in shares of Genmab A/S in the 4th quarter valued at $257,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Genmab A/S by 134.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 61,177 shares of the company’s stock worth $1,277,000 after purchasing an additional 35,073 shares during the last quarter. Grandfield & Dodd LLC grew its holdings in Genmab A/S by 4.2% in the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company’s stock worth $704,000 after acquiring an additional 1,370 shares during the last quarter. AIMZ Investment Advisors LLC bought a new position in shares of Genmab A/S during the fourth quarter valued at about $3,525,000. Finally, Bank of New York Mellon Corp grew its position in shares of Genmab A/S by 4.0% in the 4th quarter. Bank of New York Mellon Corp now owns 71,623 shares of the company’s stock worth $1,495,000 after buying an additional 2,749 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Wall Street Analysts Forecast Growth

GMAB has been the subject of several research analyst reports. Sanford C. Bernstein raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target for the company in a research report on Thursday, February 13th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Thursday, January 23rd. Finally, BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 11th. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Stock Performance

Shares of NASDAQ:GMAB opened at $19.90 on Friday. The business has a 50-day simple moving average of $20.89 and a two-hundred day simple moving average of $21.88. Genmab A/S has a fifty-two week low of $18.64 and a fifty-two week high of $30.50. The firm has a market cap of $13.17 billion, a price-to-earnings ratio of 11.44, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, research analysts predict that Genmab A/S will post 1.45 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.